Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.52 |
| ▸ | DRD3 | P35462 | 3/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6313945 | 0.98 | RECQL (0.52) | DRD2DRD3ADRA1ARECQLIGF1R | |
| SCHEMBL6068410 | 0.86 | DRD2 (0.50) | DRD2DRD3ADRA1ARECQLIGF1R | |
| SCHEMBL6068415 | 0.84 | RECQL (0.55) | DRD2DRD3ADRA1ARECQLIGF1R | |
| SCHEMBL6068501 | 0.84 | ADRA1A (0.55) | DRD2DRD3ADRA1ARECQLMEN1 | |
| SCHEMBL6311976 | 0.82 | GAA (0.46) | DRD2ADRA1AMEN1KMT2AHTR1A | |
| SCHEMBL6068249 | 0.81 | DRD2 (0.55) | DRD2MEN1KMT2A | |
| SCHEMBL13698446 | 0.81 | DRD2 (0.61) | DRD2DRD3ADRA1AHTR1A | |
| SCHEMBL6068479 | 0.81 | DRD2 (0.54) | DRD2DRD3ADRA1ARECQLMEN1 | |
| SCHEMBL7758380 | 0.79 | DRD2 (0.61) | DRD2DRD3ADRA1AMEN1KMT2A | |
| SCHEMBL6068262 | 0.79 | ALDH1A1 (0.57) | DRD2DRD3ADRA1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6696450-B2 | Serotonergic agents with long-acting in vivo effects | WYETH | 2004-02-24 | — | — | US | claimed |
| US-20030191135-A1 | Serotonergic agents with long-acting in vivo effects | WYETH | 2003-10-09 | — | — | US | claimed |
| US-6518272-B2 | HT3 receptor agonists and antagonists; treatment of anxiety, depression, cognitive deficits, and prostate cancer | WYETH | 2003-02-11 | — | — | US | claimed |
| WO-2002085871-A2 | SEROTONERGIC AGENTS WITH LONG-ACTING IN VIVO EFFECTS | WYETH (US) | 2002-10-31 | — | — | WO | claimed |
| US-20020156075-A1 | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents | WYETH (FORMERLY AMERICAN HOME PRODUCTS CORPORATION) (US) | 2002-10-24 | — | — | US | claimed |
| US-6376494-B1 | USED IN THE TREATMENT OF ANXIETY AND DEPRESSION | AMERICAN HOME PRODUCTS CORPORATION | 2002-04-23 | — | — | US | claimed |
| US-7049330-B2 | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents | WYETH (US) | 2006-05-23 | — | — | US | disclosed |
| US-20050202412-A1 | Serotonergic agents with long-acting in vivo effects | WYETH (US) | 2005-09-15 | — | — | US | disclosed |
| US-6894053-B2 | Serotonergic agents with long-acting in vivo effects | WYETH (US) | 2005-05-17 | — | — | US | disclosed |
| US-20040127505-A1 | Serotonergic Agents with long-acting in vivo effects | WYETH (US) | 2004-07-01 | — | — | US | disclosed |
| US-6696450-B2 | Serotonergic agents with long-acting in vivo effects | WYETH | 2004-02-24 | — | — | US | disclosed |
| US-20030191135-A1 | Serotonergic agents with long-acting in vivo effects | WYETH | 2003-10-09 | — | — | US | disclosed |
| US-20030139449-A1 | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents | WYETH (US) | 2003-07-24 | — | — | US | disclosed |
| US-6518272-B2 | HT3 receptor agonists and antagonists; treatment of anxiety, depression, cognitive deficits, and prostate cancer | WYETH | 2003-02-11 | — | — | US | disclosed |
| WO-2002085871-A2 | SEROTONERGIC AGENTS WITH LONG-ACTING IN VIVO EFFECTS | WYETH (US) | 2002-10-31 | — | — | WO | disclosed |
| US-20020156075-A1 | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents | WYETH (FORMERLY AMERICAN HOME PRODUCTS CORPORATION) (US) | 2002-10-24 | — | — | US | disclosed |
| US-6376494-B1 | USED IN THE TREATMENT OF ANXIETY AND DEPRESSION | AMERICAN HOME PRODUCTS CORPORATION | 2002-04-23 | — | — | US | disclosed |
| EP-1087954-A1 | CYCLOALKYL-SUBSTITUTED ARYL-PIPERAZINES, PIPERIDINES AND TETRAHYDROPYRIDINES AS SEROTONERGIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065887-A1 | CYCLOALKYL-SUBSTITUTED ARYL-PIPERAZINES, PIPERIDINES AND TETRAHYDROPYRIDINES AS SEROTONERGIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127505-A1 | Serotonergic Agents with long-acting in vivo effects | HTR1A, TPH1, TPH2 | DRD2 79/4885DRD3 131/4885ADRA1A 23/4885 |
| US-20030139449-A1 | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents | HTR5A, MC5R, CHRNA5 | DRD2 59/4885DRD3 65/4885ADRA1A 36/4885 |
| US-20030191135-A1 | Serotonergic agents with long-acting in vivo effects | HTR1A, TPH1, TPH2 | DRD2 79/4885DRD3 131/4885ADRA1A 23/4885 |
| US-20020156075-A1 | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents | HTR5A, MC5R, CHRNA5 | DRD2 59/4885DRD3 65/4885ADRA1A 36/4885 |
| US-20050202412-A1 | Serotonergic agents with long-acting in vivo effects | HTR1A, HTR5A, TPH1 | DRD2 51/4885DRD3 106/4885ADRA1A 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.